Cao X, Du X, Jiao H, An Q, Chen R, Fang P
Acta Pharm Sin B. 2022; 12(10):3783-3821.
PMID: 36213536
PMC: 9532563.
DOI: 10.1016/j.apsb.2022.05.020.
Sivets G, Amblard F, Schinazi R
Tetrahedron. 2021; 75(13):2037-2046.
PMID: 34316083
PMC: 8313018.
DOI: 10.1016/j.tet.2019.02.027.
Sharmila Tagore S, Swaminathan J, Manikandan D, Gomathi S, Sabarinathan N, Ramalingam M
Heliyon. 2021; 7(4):e06593.
PMID: 33997363
PMC: 8102761.
DOI: 10.1016/j.heliyon.2021.e06593.
Bryksova M, Hybenova A, Hernandiz A, Novak O, Pencik A, Spichal L
Front Plant Sci. 2020; 11:599228.
PMID: 33362831
PMC: 7758400.
DOI: 10.3389/fpls.2020.599228.
Molteni A, Riva M, Ravano E, Marbello L, Mancini V, Grillo G
Int J Hematol. 2017; 105(6):769-776.
PMID: 28220349
DOI: 10.1007/s12185-017-2198-0.
Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs.
Shelton J, Lu X, Hollenbaugh J, Cho J, Amblard F, Schinazi R
Chem Rev. 2016; 116(23):14379-14455.
PMID: 27960273
PMC: 7717319.
DOI: 10.1021/acs.chemrev.6b00209.
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
Burnett A, Russell N, Hills R, Kell J, Nielsen O, Dennis M
Leukemia. 2016; 31(2):310-317.
PMID: 27624670
PMC: 5292678.
DOI: 10.1038/leu.2016.225.
Clofarabine and Cytarabine Regimen for Acute Myeloid Leukemia.
Ho K, Solimando Jr D, Waddell J
Hosp Pharm. 2016; 50(11):969-74.
PMID: 27621503
PMC: 4750846.
DOI: 10.1310/hpj5011-969.
Studies toward the oxidative and reductive activation of C-S bonds in 2'--aryl-2'-thiouridine derivatives.
Rayala R, Giuglio-Tonolo A, Broggi J, Terme T, Vanelle P, Theard P
Tetrahedron. 2016; 72(16):1969-1977.
PMID: 27019535
PMC: 4806340.
DOI: 10.1016/j.tet.2016.02.063.
The chemoenzymatic synthesis of clofarabine and related 2'-deoxyfluoroarabinosyl nucleosides: the electronic and stereochemical factors determining substrate recognition by E. coli nucleoside phosphorylases.
Fateev I, Antonov K, Konstantinova I, Muravyova T, Seela F, Esipov R
Beilstein J Org Chem. 2014; 10:1657-69.
PMID: 25161724
PMC: 4142866.
DOI: 10.3762/bjoc.10.173.
AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
Cooper T, Alonzo T, Gerbing R, Perentesis J, Whitlock J, Taub J
Cancer. 2014; 120(16):2482-9.
PMID: 24771494
PMC: 4126862.
DOI: 10.1002/cncr.28674.
Structural characterization of new deoxycytidine kinase inhibitors rationalizes the affinity-determining moieties of the molecules.
Nomme J, Murphy J, Su Y, Sansone N, Armijo A, Olson S
Acta Crystallogr D Biol Crystallogr. 2014; 70(Pt 1):68-78.
PMID: 24419380
PMC: 3919262.
DOI: 10.1107/S1399004713025030.
Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.
Jacoby M, Martin M, Uy G, Westervelt P, Dipersio J, Cashen A
Am J Hematol. 2014; 89(5):487-92.
PMID: 24415560
PMC: 4378713.
DOI: 10.1002/ajh.23663.
New insights into the synergism of nucleoside analogs with radiotherapy.
Lee M, Parker W, Xu B
Radiat Oncol. 2013; 8:223.
PMID: 24066967
PMC: 3851323.
DOI: 10.1186/1748-717X-8-223.
Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age.
Vigil C, Tan W, Deeb G, Sait S, Block A, Starostik P
Leuk Res. 2013; 37(11):1468-71.
PMID: 24011826
PMC: 3818466.
DOI: 10.1016/j.leukres.2013.07.036.
Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives.
Magnani C, Tettamanti S, Maltese F, Turazzi N, Biondi A, Biagi E
Front Oncol. 2013; 3:106.
PMID: 23641364
PMC: 3639447.
DOI: 10.3389/fonc.2013.00106.
Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
Cooper T, Razzouk B, Gerbing R, Alonzo T, Adlard K, Raetz E
Pediatr Blood Cancer. 2013; 60(7):1141-7.
PMID: 23335239
PMC: 4605828.
DOI: 10.1002/pbc.24398.
Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling.
Thudium K, Ghoshal S, Fetterly G, Den Haese J, Karpf A, Wetzler M
Leuk Res. 2012; 36(11):1410-6.
PMID: 22884950
PMC: 3457067.
DOI: 10.1016/j.leukres.2012.07.015.
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R
J Clin Oncol. 2012; 30(20):2492-9.
PMID: 22585697
PMC: 4874149.
DOI: 10.1200/JCO.2011.37.9743.
Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults.
Litzow M
Drugs. 2011; 71(4):415-42.
PMID: 21395356
DOI: 10.2165/11588950-000000000-00000.